Drug Trial Radar · NCT05743907
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Apr 25, 2023
Primary completion
Mar 10, 2025
Study completion Mar 10, 2025
Sponsor
- Lead sponsor
- Dong-A ST Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control
Conditions
- Diabetes Mellitus
Interventions
DA-2811Drug
DA-2811 Group: DA-2811 + Forxiga placebo
ForxigaDrug
Forxiga Group: Forxiga + DA-2811 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c(%)Time frame: Change from baseline at 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea Bucheon St. Mary's Hospital
Bucheon-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.